cilomilast has been researched along with milrinone in 5 studies
| Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) | Studies (milrinone) | Trials (milrinone) | Recent Studies (post-2010) (milrinone) |
|---|---|---|---|---|---|
| 162 | 13 | 42 | 1,605 | 235 | 452 |
| Protein | Taxonomy | cilomilast (IC50) | milrinone (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 1 | |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.3 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.3 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.52 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.7 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.15 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 1.8674 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 1.8177 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | 5 | |
| Phosphodiesterase | Sus scrofa (pig) | 0.843 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, RA; Manallack, DT; Thompson, PE | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Guan, Q; Montrose, DC; Quilley, J; Rajagopalan, S; Smith, CJ; Zhao, H | 1 |
1 review(s) available for cilomilast and milrinone
| Article | Year |
|---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
4 other study(ies) available for cilomilast and milrinone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Milrinone; Nitriles; Phosphodiesterase Inhibitors; Phosphorylation; Quinolones; Rats; Rats, Sprague-Dawley; Tetrazoles; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2007 |